doi:10.3969/j.issn.1673-8640.2022.09.010

Abstract

CLC Number:

R446.11

Figures/Tables 2

References 15

[1]	O'RIORDAN M N, HIGGINS J R. Haemostasis in normal and abnormal pregnancy[J]. Best Pract Res Clin Obstet Gynaecol, 2003, 17(3):385-396. DOI URL
[2]	CERNECA F, RICCI G, SIMEONE R, et al. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state,combined with a reactive fibrinolysis[J]. Eur J Obstet Gynecol Reprod Biol, 1997, 73(1):31-36. DOI URL
[3]	UCHIKOVA E H, LEDJEV I I. Changes in haemostasis during normal pregnancy[J]. Eur J Obstet Gynecol Reprod Biol, 2005, 119(2):185-188. PMID
[4]	陈慧芬. 产科易栓症的检测在反复自然流产病因诊断中的临床价值[J]. 中华检验医学杂志, 2017, 40(11):856-859.
[5]	谢幸, 孔北华, 段涛, 等. 妇产科学[M]. 9版. 北京: 人民卫生出版社, 2018.
[6]	KUPFERMINC M J, ELDOR A, STEINMAN N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy[J]. N Engl J Med, 1999, 340(1):9-13. DOI URL
[7]	BREMME K, OSTLUND E, ALMQVIST I, et al. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium[J]. Obstet Gynecol, 1992, 80(1):132-137. PMID
[8]	WICKSTRÖM K, EDELSTAM G, LÖWBEER C H, et al. Reference intervals for plasma levels of fibronectin,von-Willebrand factor,free protein S,and antithrombin during third-trimester pregnancy[J]. Scand J Clin Lab Invest, 2004, 64(1):31-40. DOI URL
[9]	LEFKOWITZ J B, CLARKE S H, BARBOUR L A. Comparison of protein S functional and antigenic assays in normal pregnancy[J]. Am J Obstet Gynecol, 1996, 175(<W>3 Pt 1):657-660. DOI URL
[10]	ORUÇ S, SARUÇ M, KOYUNCU F M, et al. Changes in plasma activities of protein C and protein S during pregnancy[J]. Aust N Z J Obstet Gynaecol, 2000, 40(4):448-450. DOI URL
[11]	SAID J M, IGNJATOVIC V, MONAGLE P T, et al. Altered reference ranges for protein C and protein S during early pregnancy:implications for the diagnosis of protein C and protein S deficiency during pregnancy[J]. Thromb Haemost, 2010, 103(5):984-988. DOI URL
[12]	於王骐, 陈兆军, 袁园, 等. 健康妇女孕期抗凝指标的变化[J]. 中国卫生检验杂志, 2019, 29(9):1108-1110.
[13]	NAKASHIMA A, KOBAYASHI T, TERAO T. Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors[J]. Gynecol Obstet Invest, 1996, 42(2):95-101.
[14]	COOLMAN M, DE GROOT C J, STEEGERS E A, et al. Concentrations of plasminogen activators and their inhibitors in blood preconceptionally,during and after pregnancy[J]. Eur J Obstet Gynecol Reprod Biol, 2006, 128(1-2):22-28. DOI URL
[15]	CHEN H, NIE S, LU M. Association between plasminogen activator inhibitor-1 gene polymorphisms and recurrent pregnancy loss:a systematic review and meta-analysis[J]. Am J Reprod Immunol, 2015, 73(4):292-300. DOI URL

组别	例数	蛋白活性C/%	蛋白活性S/%	纤溶酶原活性/%
正常对照组	241	110.3（100.7~124.3）	83.0（75.8~97.0）	102.3（92.3~111.2）
孕早期组	242	108.0（96.8~119.6）	46.8（34.5~60.0）^*	117.1（101.4~130.1）^*
孕中期组	256	115.3（100.5~130.4）^#	41.1（32.6~50.0）^*#	150.8 （139.0~168.3）^*#
孕晚期组	261	113.1（97.8~129.8）^#	40.6（31.9~48.1）^*#	152.9 （135.6~173.7）^*#

组别	例数	蛋白活性C/%	蛋白活性S/%	纤溶酶原活性/%
正常对照组	241	110.3（100.7~124.3）	83.0（75.8~97.0）	102.3（92.3~111.2）
孕早期组	242	108.0（96.8~119.6）	46.8（34.5~60.0）^*	117.1（101.4~130.1）^*
孕中期组	256	115.3（100.5~130.4）^#	41.1（32.6~50.0）^*#	150.8 （139.0~168.3）^*#
孕晚期组	261	113.1（97.8~129.8）^#	40.6（31.9~48.1）^*#	152.9 （135.6~173.7）^*#

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 15

Related Articles 15

Recommended Articles

Metrics

[1]	DENG Chenxia, MEI Yanping, ZHANG Xia, HUANG Baoshan, TIAN Dan, CAO Mengting, HU Yongqi, LIN Yongping, TIAN Lijun. Depolymerization effect of optical platelet count on reversible platelet aggregation after blood collection [J]. Laboratory Medicine, 2023, 38(11): 1087-1090.
[2]	LU Tingyan, GU Danfeng, WANG Yahong, GE Yafang, YANG Haiou. Evaluation of vaginal secretion routine determination modes and review criteria analysis [J]. Laboratory Medicine, 2023, 38(11): 1091-1097.
[3]	. [J]. Laboratory Medicine, 2023, 38(11): 1098-1100.
[4]	. [J]. Laboratory Medicine, 2023, 38(10): 983-986.
[5]	. [J]. Laboratory Medicine, 2023, 38(9): 901-904.
[6]	. [J]. Laboratory Medicine, 2023, 38(9): 905-908.
[7]	CHENG Xu, YANG Cunqing, PANG Bo, GU Chun, HOU Xueyun, FEI Jiaxin, WU Min, LI Jun, LIU Guijian. Number and activity of peripheral blood eosinophils in obese people [J]. Laboratory Medicine, 2023, 38(9): 855-859.
[8]	LEI Jing, MAN Qiuhong, ZHAO Renjia, ZHANG Tiejun, JIANG Yanfeng, XU Kelin, SUO Chen, CHEN Xingdong. Elevated red blood cell distribution width increasing the risk of heart failure：a cohort study based on the UK Biobank [J]. Laboratory Medicine, 2023, 38(9): 860-864.
[9]	DUAN Lili, JIANG Chang, ZHOU Dongmei. Role of PLR in ankylosing spondylitis patients with positive antinuclear antibody [J]. Laboratory Medicine, 2023, 38(7): 669-674.
[10]	XIA Yanyan, XIA Yongquan, SONG Guanghao, XIA Mao. Role of coagulation-related monitoring indicators in the course of rivaroxaban anticoagulation for acute venous thromboembolism in elderly patients [J]. Laboratory Medicine, 2023, 38(5): 475-478.
[11]	CHEN Yi, WANG Jia, XU Zhiwei, ZHAI Yaping, XUAN Weixia. Effects of different anticoagulants on phagocytosis，activation and apoptosis of in vitro neutrophil function [J]. Laboratory Medicine, 2023, 38(5): 479-483.
[12]	YANG Liyuan, DAI Wanqin, WANG Xiaotong, LOU Xiaoli, WANG Yue, HOU Yanqiang. Effect of peripheral blood neutrophils on interferon-gamma release assay of Mycobacterium tuberculosis [J]. Laboratory Medicine, 2023, 38(5): 484-488.
[13]	. [J]. Laboratory Medicine, 2023, 38(5): 502-504.
[14]	. [J]. Laboratory Medicine, 2023, 38(1): 69-72.
[15]	XIE Yuan, YI Wanwan, SHI Qiuyuan, LÜ Zhongwei, LIU Jin. Clinical value of thromboelastography and conventional coagulation tests in evaluating coagulation status of colon cancer and colon polyps [J]. Laboratory Medicine, 2022, 37(11): 1007-1011.